|
Acidosis, Lactic
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The currently available α-glucosidase inhibitors, for instance, acarbose have some side effects such as hypoglycemia at higher doses, liver problems, meteorism, diarrhea, and lactic acidosis.
|
31553294 |
2020 |
|
Sudden infant death syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
SID is a condition in which sucrase-isomaltase, an enzyme produced by brush border of small intestine to metabolize sucrose, is deficient.
|
31493040 |
2020 |
|
Cortical cataract
|
0.010 |
Biomarker
|
disease |
BEFREE |
After adjusting for age, gender, ethnicity, body mass index, smoking status, socioeconomic status, hypertension, hyperlipidaemia, diabetes, duration of diabetes and cardiovascular disease, ACE inhibitors (OR=1.27; 95% CI 1.05 to 1.55), fibrates (OR=1.57; 95% CI 1.05 to 2.35), alpha-glucosidase inhibitors (AGIs) (OR=1.85; 95% CI 1.13 to 3.02) and insulin (OR=1.80; 95% CI 1.11 to 2.93) were significantly associated with the presence of cortical cataract.
|
31272959 |
2020 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Corn silk (Zea mays L.), a source of natural antioxidants with α-amylase, α-glucosidase, advanced glycation and diabetic nephropathy inhibitory activities.
|
30530231 |
2019 |
|
Neuromuscular Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Pompe disease is a neuromuscular disease caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase leading to lysosomal and cytoplasmic glycogen accumulation in neurons and striated muscle.
|
31392202 |
2019 |
|
Tremor
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The α-glucosidase activity in shake flasks reached 107.9 U/mL and using 4-Nitrophenyl β-D-glucopyranoside (<i>p</i>NPG) as substrate, the <i>K</i><sub>m</sub> and <i>Vmax</i> values were 2.321 mM and 306.3 U/mg, respectively.
|
30974879 |
2019 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
α-glucosidase inhibitors (AGIs) are very attractive bioactive compounds due to their therapeutic profile that includes beneficial effects over glycemic control in type 2 diabetes mellitus and viral infections.
|
31402104 |
2019 |
|
Hypertensive heart failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We investigated the impact of the cardio-intestinal association on hypertensive heart failure using miglitol, an α-glucosidase inhibitor known to stimulate intestinal GLP-1 production.
|
30629149 |
2019 |
|
Collecting Duct Carcinoma of the Kidney
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus BDC significantly inhibited α-glucosidase in comparison to acarbose.
|
30594450 |
2019 |
|
Brachydactyly type C
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus BDC significantly inhibited α-glucosidase in comparison to acarbose.
|
30594450 |
2019 |
|
Dystrophia myotonica 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
α-Glucosidase is considered as a therapeutic target for the treatment of type 2 diabetes mellitus (DM2).
|
31369977 |
2019 |
|
Heart failure with normal ejection fraction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial.
|
30928954 |
2019 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, the interaction mechanism of SAA and AG was investigated by multi-spectroscopic methods along with molecular docking.
|
30954797 |
2019 |
|
Heart failure with preserved ejection fraction [HFpEF]
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the ongoing MUSCAT-HF (It stands for Prospective Comparison of Luseogliflozin and Alpha-glucosidase on the Management of Diabetic Patients with Chronic Heart Failure and Preserved Ejection Fraction) trial is to evaluate the efficacy of luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus voglibose, an alpha-glucosidase inhibitor, using brain natriuretic peptide (BNP) as the index of therapeutic effect in T2DM patients with HFpEF.
|
30928954 |
2019 |
|
Constipation
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Overall, 90.4% of patients in the biguanide group, 83.6% in the thiazolidinedione group, 83.6% in the alpha-glucosidase group and 85.3% in the glinide group reported one or more treatment-emergent adverse event, the most common of which were nasopharingitis, nausea and constipation.
|
28429860 |
2018 |
|
Dengue Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we established Huh7.5-derived cell lines with ER α-glucosidase I or II knockout using CRISPR/Cas9 and demonstrated that the replication of Dengue, Yellow fever and Zika viruses was reduced by only 1-2 logs in the knockout cell lines.
|
29253498 |
2018 |
|
Gaucher Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We tested the encapsulation strategy on four enzymes currently investigated for enzyme replacement therapy: palmitoyl protein thioesterase 1 (PPT1; defective in NCL1 disease), galactosylceramidase (GALC; defective in globoid cell leukodystrophy), alpha glucosidase (aGLU; defective in Pompe disease), and beta glucosidase (bGLU; defective in Gaucher's disease).
|
29894633 |
2018 |
|
Hemorrhagic Fevers, Viral
|
0.010 |
Biomarker
|
disease |
BEFREE |
Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.
|
29253498 |
2018 |
|
Hypercholesterolemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Acarbose, an alpha-glucosidase inhibitor, has been demonstrated to not affect serum levels of glucose and decrease the progression of intima-media thickening in rabbits fed with a high cholesterol diet (HCD).
|
29432898 |
2018 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The objective of this paper is to evaluate the variations in the ability of Pistacia atlantica leaves to inhibit enzymes linked to type 2 diabetes (α-amylase and α-glucosidase) and to hypertension (angiotensin converting enzyme-I (ACE-I)), depending on harvesting month, gender and growing region, as well as to identify the peaks in chromatographic fingerprints that potentially correspond to components with enzymatic inhibitory activities.
|
29190580 |
2018 |
|
Inflammatory Bowel Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we show, using Caco-2 cells as a model of intestinal epithelial barrier, that inducing ER stress using a cocktail mixture of pro-inflammatory mediators [TNFα (50ng/ml), MCP1 (50ng/ml), and IL-1β (25ng/ml)] as observed in IBD patients induces ER stress and leads to significant changes in key proteins of the apical (sucrase-isomaltase (SI), dipeptidyl-peptidase (DPPIV), and ezrin) and basolateral (E-cadherin, zonula occludens (ZO-1), and connexin-43) membranes.
|
29324356 |
2018 |
|
Niemann-Pick Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To test whether reduction in lysosomal enzymatic activity in PD is specific to GCase, we measured GCase, acid sphingomyelinase (deficient in Niemann-Pick disease types A and B), alpha galactosidase A (deficient in Fabry), acid alpha-glucosidase (deficient in Pompe) and galactosylceramidase (deficient in Krabbe) enzymatic activities in dried blood spots of PD patients (n = 648) and controls (n = 317) recruited from Columbia University.
|
29369793 |
2018 |
|
Prolactinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compounds 1-3 showed α-glucosidase inhibitory activity with IC<sub>50</sub> ranging from 8.1 to 11.2 μM, and compound 1 exhibited potent cytotoxicity against rat prolactinoma MMQ and rat pituitary adenoma GH3 cell lines (IC<sub>50</sub> = 3.09 and 3.64 μM).
|
29022767 |
2018 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
The results demonstrate that ultrafiltration with liquid chromatography and mass spectrometry combined with high-speed counter-current chromatography is not only a powerful tool for screening and isolating α-glucosidase and lactate dehydrogenase inhibitors in complex samples, but also a useful platform for identifying bioactive compounds for preventing and treating diabetes and stroke.
|
30444083 |
2018 |
|
Muscle damage
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Pompe disease results from lysosomal acid α-glucosidase (GAA) deficiency and its associated glycogen accumulation and muscle damage.
|
29565424 |
2018 |